AU2003245523A1 - Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g) - Google Patents

Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g) Download PDF

Info

Publication number: AU2003245523A1
Authority: AU; Australia
Prior art keywords: ring; group; alkyl; alkandiyl; rests
Prior art date: 2002-02-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003245523A

Other languages

English (en)

Inventor

Thorsten Blume

Wolf-Dietrich Docke

Bernd Elger

Wolfgang Halfbrodt

Joachim Kuhnke

Ursula Monning

Herbert Schneider

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Bayer Schering Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-15

Filing date

2003-01-17

Publication date

2003-09-04

2003-01-17 Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG

2003-09-04 Publication of AU2003245523A1 publication Critical patent/AU2003245523A1/en

2008-01-31 Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Alteration of Name(s) of Applicant(s) under S113 Assignors: SCHERING AKTIENGESELLSCHAFT

Status Abandoned legal-status Critical Current

Links

102000013462 Interleukin-12 Human genes 0.000 title claims description 37
108010065805 Interleukin-12 Proteins 0.000 title claims description 37
210000000274 microglia Anatomy 0.000 title claims description 18
229940117681 interleukin-12 Drugs 0.000 title claims description 12
239000003112 inhibitor Substances 0.000 title claims description 11
230000008105 immune reaction Effects 0.000 title claims description 6
-1 butan-1,4-diyl group Chemical group 0.000 claims description 46
229910052760 oxygen Inorganic materials 0.000 claims description 44
125000001072 heteroaryl group Chemical group 0.000 claims description 43
229910052717 sulfur Inorganic materials 0.000 claims description 26
238000004519 manufacturing process Methods 0.000 claims description 25
125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
125000003118 aryl group Chemical group 0.000 claims description 22
150000001875 compounds Chemical group 0.000 claims description 22
125000004430 oxygen atom Chemical group O* 0.000 claims description 22
210000001744 T-lymphocyte Anatomy 0.000 claims description 21
125000005842 heteroatom Chemical group 0.000 claims description 21
230000001404 mediated effect Effects 0.000 claims description 21
229910052757 nitrogen Inorganic materials 0.000 claims description 21
125000000217 alkyl group Chemical class 0.000 claims description 20
125000004432 carbon atom Chemical group C* 0.000 claims description 19
101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims description 18
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
125000000623 heterocyclic group Chemical group 0.000 claims description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
206010061218 Inflammation Diseases 0.000 claims description 13
230000004054 inflammatory process Effects 0.000 claims description 13
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
125000000753 cycloalkyl group Chemical class 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
229940079593 drug Drugs 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
229910052739 hydrogen Inorganic materials 0.000 claims description 11
201000010099 disease Diseases 0.000 claims description 10
210000001616 monocyte Anatomy 0.000 claims description 10
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
206010040070 Septic Shock Diseases 0.000 claims description 8
229910052799 carbon Inorganic materials 0.000 claims description 8
208000026278 immune system disease Diseases 0.000 claims description 8
125000001424 substituent group Chemical group 0.000 claims description 8
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 7
125000004434 sulfur atom Chemical group 0.000 claims description 7
208000023275 Autoimmune disease Diseases 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 6
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 5
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 5
230000000172 allergic effect Effects 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
210000002540 macrophage Anatomy 0.000 claims description 5
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 4
208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
206010040047 Sepsis Diseases 0.000 claims description 4
206010044248 Toxic shock syndrome Diseases 0.000 claims description 4
231100000650 Toxic shock syndrome Toxicity 0.000 claims description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
101001124876 Xenopus laevis Nodal homolog 4-A Proteins 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
206010003246 arthritis Diseases 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
125000004429 atom Chemical group 0.000 claims description 4
208000010668 atopic eczema Diseases 0.000 claims description 4
125000001589 carboacyl group Chemical group 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
208000002296 eclampsia Diseases 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
208000035473 Communicable disease Diseases 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 3
206010012442 Dermatitis contact Diseases 0.000 claims description 3
208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
125000003342 alkenyl group Chemical class 0.000 claims description 3
208000026935 allergic disease Diseases 0.000 claims description 3
208000010247 contact dermatitis Diseases 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
231100000673 dose–response relationship Toxicity 0.000 claims description 3
208000024908 graft versus host disease Diseases 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
206010025135 lupus erythematosus Diseases 0.000 claims description 3
230000003959 neuroinflammation Effects 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
201000000306 sarcoidosis Diseases 0.000 claims description 3
238000006467 substitution reaction Methods 0.000 claims description 3
208000023328 Basedow disease Diseases 0.000 claims description 2
206010006895 Cachexia Diseases 0.000 claims description 2
208000000059 Dyspnea Diseases 0.000 claims description 2
206010013975 Dyspnoeas Diseases 0.000 claims description 2
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 2
208000015023 Graves' disease Diseases 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
241000721454 Pemphigus Species 0.000 claims description 2
206010035664 Pneumonia Diseases 0.000 claims description 2
206010035742 Pneumonitis Diseases 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
229910052770 Uranium Inorganic materials 0.000 claims description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
206010009887 colitis Diseases 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
125000001041 indolyl group Chemical group 0.000 claims description 2
238000002483 medication Methods 0.000 claims description 2
KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 claims description 2
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 2
230000008816 organ damage Effects 0.000 claims description 2
230000036303 septic shock Effects 0.000 claims description 2
208000013220 shortness of breath Diseases 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
231100000331 toxic Toxicity 0.000 claims description 2
230000002588 toxic effect Effects 0.000 claims description 2
230000009385 viral infection Effects 0.000 claims description 2
208000001204 Hashimoto Disease Diseases 0.000 claims 1
208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
102000014150 Interferons Human genes 0.000 claims 1
108010050904 Interferons Proteins 0.000 claims 1
229940079322 interferon Drugs 0.000 claims 1
208000028774 intestinal disease Diseases 0.000 claims 1
230000010412 perfusion Effects 0.000 claims 1
239000000126 substance Substances 0.000 description 45
210000004027 cell Anatomy 0.000 description 34
230000005764 inhibitory process Effects 0.000 description 18
239000000243 solution Substances 0.000 description 18
239000013543 active substance Substances 0.000 description 13
150000001556 benzimidazoles Chemical class 0.000 description 13
229920006008 lipopolysaccharide Polymers 0.000 description 12
230000000638 stimulation Effects 0.000 description 12
210000000601 blood cell Anatomy 0.000 description 11
238000005516 engineering process Methods 0.000 description 11
239000002253 acid Substances 0.000 description 10
229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
238000005119 centrifugation Methods 0.000 description 9
235000002639 sodium chloride Nutrition 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
230000028327 secretion Effects 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
239000012980 RPMI-1640 medium Substances 0.000 description 7
210000002443 helper t lymphocyte Anatomy 0.000 description 7
239000007788 liquid Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
239000000203 mixture Substances 0.000 description 7
210000005239 tubule Anatomy 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical class N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
108700012920 TNF Proteins 0.000 description 6
230000004913 activation Effects 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
102000008070 Interferon-gamma Human genes 0.000 description 5
108010074328 Interferon-gamma Proteins 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000006698 induction Effects 0.000 description 5
229960003130 interferon gamma Drugs 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000002585 base Substances 0.000 description 4
150000001721 carbon Chemical class 0.000 description 4
239000008298 dragée Substances 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
238000011316 allogeneic transplantation Methods 0.000 description 3
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000005755 formation reaction Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
201000006747 infectious mononucleosis Diseases 0.000 description 3
230000019734 interleukin-12 production Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
230000035939 shock Effects 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
238000008157 ELISA kit Methods 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
101150106931 IFNG gene Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
208000034189 Sclerosis Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000004040 coloring Methods 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
210000001787 dendrite Anatomy 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
229940031098 ethanolamine Drugs 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000031261 interleukin-10 production Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000001991 pathophysiological effect Effects 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
239000000049 pigment Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
238000004321 preservation Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000000518 rheometry Methods 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000013519 translation Methods 0.000 description 2
FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 description 1
125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
GZPMMQGPHXEMSZ-UHFFFAOYSA-N 1-(methoxymethyl)pyrrolidine Chemical compound COCN1CCCC1 GZPMMQGPHXEMSZ-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
HNVIQLPOGUDBSU-UHFFFAOYSA-N 2,6-dimethylmorpholine Chemical compound CC1CNCC(C)O1 HNVIQLPOGUDBSU-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
KXLVUPHAFOESOH-UHFFFAOYSA-N 6-hexoxy-1-(4-methylphenyl)-2-phenylbenzimidazole Chemical compound CC1=CC=C(C=C1)N1C(=NC2=C1C=C(C=C2)OCCCCCC)C1=CC=CC=C1 KXLVUPHAFOESOH-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
239000004397 EU approved solvent Substances 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
208000034800 Leukoencephalopathies Diseases 0.000 description 1
208000009829 Lewy Body Disease Diseases 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000000609 Pick Disease of the Brain Diseases 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
229940126530 T cell activator Drugs 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
238000006887 Ullmann reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
150000001337 aliphatic alkines Chemical class 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000006193 alkinyl group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229920006237 degradable polymer Polymers 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229940093476 ethylene glycol Drugs 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
102000052620 human IL10 Human genes 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
231100000835 liver failure Toxicity 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000006764 neuronal dysfunction Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
UWBHMRBRLOJJAA-UHFFFAOYSA-N oxaluric acid Chemical compound NC(=O)NC(=O)C(O)=O UWBHMRBRLOJJAA-UHFFFAOYSA-N 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
239000011505 plaster Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000011814 protection agent Substances 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
239000004945 silicone rubber Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
229940100640 transdermal system Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

AU2003245523A 2002-02-15 2003-01-17 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g) Abandoned AU2003245523A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10207843A DE10207843A1 (de)	2002-02-15	2002-02-15	Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
DE10207843.2		2002-02-15
PCT/EP2003/000467 WO2003068225A1 (de)	2002-02-15	2003-01-17	Mikroglia-inhibitoren zur unterbrechung von interleukin 12 und ifn-gamma vermittelten immunreaktionen

Publications (1)

Publication Number	Publication Date
AU2003245523A1 true AU2003245523A1 (en)	2003-09-04

Family

ID=27674912

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003245523A Abandoned AU2003245523A1 (en)	2002-02-15	2003-01-17	Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)

Country Status (21)

Country	Link
EP (1)	EP1474138A1 (de)
JP (1)	JP2005522447A (de)
KR (1)	KR20040084909A (de)
CN (1)	CN1756546A (de)
AR (1)	AR039556A1 (de)
AU (1)	AU2003245523A1 (de)
BR (1)	BR0307706A (de)
CA (1)	CA2475770A1 (de)
DE (1)	DE10207843A1 (de)
EC (1)	ECSP045297A (de)
MX (1)	MXPA04007943A (de)
NO (1)	NO20043840L (de)
PE (1)	PE20030906A1 (de)
PL (1)	PL371327A1 (de)
RS (1)	RS71304A (de)
RU (1)	RU2004127677A (de)
TW (1)	TW200306823A (de)
UA (1)	UA81111C2 (de)
UY (1)	UY27662A1 (de)
WO (1)	WO2003068225A1 (de)
ZA (1)	ZA200407382B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10207844A1 (de) *	2002-02-15	2003-09-04	Schering Ag	1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE602005016729D1 (de) *	2005-03-17	2009-10-29	Proyecto Biomedicina Cima Sl	Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
WO2013186229A1 (en) *	2012-06-11	2013-12-19	Ucb Pharma S.A.	Tnf -alpha modulating benzimidazoles
US9586949B2 (en)	2015-02-09	2017-03-07	Incyte Corporation	Aza-heteroaryl compounds as PI3K-gamma inhibitors
LT3371190T (lt)	2015-11-06	2022-08-10	Incyte Corporation	Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
DK3390367T3 (da) *	2015-12-15	2020-10-26	Univ Leland Stanford Junior	Fremgangsmåde til forebyggelse og/eller behandling af aldersrelateret kognitiv funktionsnedsættelse og neuroinflammation
AR107293A1 (es)	2016-01-05	2018-04-18	Incyte Corp	COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
US10138248B2 (en)	2016-06-24	2018-11-27	Incyte Corporation	Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
WO2019079469A1 (en)	2017-10-18	2019-04-25	Incyte Corporation	CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
CR20250050A (es)	2018-09-05	2025-03-19	Incyte Corp	Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
PL3860998T3 (pl)	2018-10-05	2024-06-17	Annapurna Bio Inc.	Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj
CN112341450B (zh) *	2019-08-09	2022-05-17	成都先导药物开发股份有限公司	一种免疫调节剂
CN112341451B (zh) *	2019-08-09	2022-06-17	成都先导药物开发股份有限公司	一种免疫调节剂
WO2021126923A1 (en) *	2019-12-19	2021-06-24	The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services	Cd206 modulators their use and methods for preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4330959A1 (de) *	1993-09-09	1995-03-16	Schering Ag	Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2396227C (en) *	2000-01-14	2012-03-20	Schering Aktiengesellschaft	1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
DE10134775A1 (de) *	2001-07-06	2003-01-30	Schering Ag	1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) *	2001-07-09	2003-02-06	Schering Ag	1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate

2002
- 2002-02-15 DE DE10207843A patent/DE10207843A1/de not_active Ceased
2003
- 2003-01-17 KR KR10-2004-7012557A patent/KR20040084909A/ko not_active Ceased
- 2003-01-17 UA UA20040907401A patent/UA81111C2/uk unknown
- 2003-01-17 CN CNA038039923A patent/CN1756546A/zh active Pending
- 2003-01-17 RS YU71304A patent/RS71304A/sr unknown
- 2003-01-17 CA CA002475770A patent/CA2475770A1/en not_active Abandoned
- 2003-01-17 PL PL03371327A patent/PL371327A1/xx not_active Application Discontinuation
- 2003-01-17 WO PCT/EP2003/000467 patent/WO2003068225A1/de not_active Ceased
- 2003-01-17 RU RU2004127677/15A patent/RU2004127677A/ru unknown
- 2003-01-17 BR BR0307706-3A patent/BR0307706A/pt not_active IP Right Cessation
- 2003-01-17 EP EP03739380A patent/EP1474138A1/de not_active Withdrawn
- 2003-01-17 JP JP2003567407A patent/JP2005522447A/ja active Pending
- 2003-01-17 AU AU2003245523A patent/AU2003245523A1/en not_active Abandoned
- 2003-01-17 MX MXPA04007943A patent/MXPA04007943A/es unknown
- 2003-02-03 PE PE2003000119A patent/PE20030906A1/es not_active Application Discontinuation
- 2003-02-11 UY UY27662A patent/UY27662A1/es not_active Application Discontinuation
- 2003-02-12 AR ARP030100436A patent/AR039556A1/es unknown
- 2003-02-14 TW TW092103072A patent/TW200306823A/zh unknown
2004
- 2004-09-14 EC EC2004005297A patent/ECSP045297A/es unknown
- 2004-09-14 ZA ZA200407382A patent/ZA200407382B/en unknown
- 2004-09-14 NO NO20043840A patent/NO20043840L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2475770A1 (en)	2003-08-21
PL371327A1 (en)	2005-06-13
UY27662A1 (es)	2003-09-30
WO2003068225A1 (de)	2003-08-21
ECSP045297A (es)	2004-10-26
KR20040084909A (ko)	2004-10-06
BR0307706A (pt)	2005-01-11
ZA200407382B (en)	2005-09-14
CN1756546A (zh)	2006-04-05
AR039556A1 (es)	2005-02-23
RU2004127677A (ru)	2005-06-10
UA81111C2 (en)	2007-12-10
EP1474138A1 (de)	2004-11-10
DE10207843A1 (de)	2003-09-04
JP2005522447A (ja)	2005-07-28
PE20030906A1 (es)	2004-01-17
TW200306823A (en)	2003-12-01
RS71304A (sr)	2006-10-27
MXPA04007943A (es)	2004-11-26
NO20043840L (no)	2004-11-12

Publication	Publication Date	Title
AU2003245523A1 (en)	2003-09-04	Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
Pukel et al.	1988	Destruction of rat islet cell monolayers by cytokines: synergistic interactions of interferon-γ, tumor necrosis factor, lymphotoxin, and interleukin 1
JP5221147B2 (ja)	2013-06-26	炎症及び免疫に関連する用途に用いる化合物
JP4990766B2 (ja)	2012-08-01	二置換型ヘテロアリール化合物
Mesaik et al.	2006	Biological and molecular docking studies on coagulin-H: Human IL-2 novel natural inhibitor
CN104703978A (zh)	2015-06-10	(s)-3-(4-((4-(吗啉代甲基)苄基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6-二酮的盐和固体形式及包含所述盐和固体形式的组合物及其使用方法
JP2008528520A (ja)	2008-07-31	炎症及び免疫に関連する用途に用いる化合物
TW201026693A (en)	2010-07-16	Compounds for inflammation and immune-related uses
EP0797448B1 (de)	2003-02-26	Kombinationspraeparat, welches cyclosporin a oder fk-506 oder rapamycin und ein xanthinderivat enthaelt
TW201018666A (en)	2010-05-16	Compounds for inflammation and immune-related uses
US20040006117A1 (en)	2004-01-08	Microglia inhibitors for interrupting interleukin 12 and IFN-gamma-mediated immune reactions
MacKay et al.	1985	Lymphoid cells of BB/W diabetic rats are cytotoxic to islet beta cells in vitro
US10550120B2 (en)	2020-02-04	Indole alkaloid compound having immune checkpoint inhibitory action
EP2771009A1 (de)	2014-09-03	Verbindungen zur verwendung gegen entzündungs- und immunspezifische erkrankungen
WO2020092650A1 (en)	2020-05-07	Compositions and methods for modulating t cell exhaustion
AU2023311505A1 (en)	2025-02-13	Continuous delivery systems comprising a cannabinoid and medicinal uses thereof
RU2325384C2 (ru)	2008-05-27	1-фенил-2-гетероарилзамещенные производные бензимидазола, их применение для получения лекарственных средств, а также содержащие эти производные фармацевтические препараты
KR20250093565A (ko)	2025-06-24	혈색소병증의 치료를 위한 화합물 및 그의 용도
US7683081B2 (en)	2010-03-23	1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
WO2022033200A1 (zh)	2022-02-17	索拉非尼在治疗1型糖尿病中的应用
JPH08501570A (ja)	1996-02-20	γ−インターフェロン産生の活性化のためのドーパミンアゴニストの使用
WO2025143482A1 (ko)	2025-07-03	금속-유기 골격체를 포함하는 수지상 세포 분화 유도용 조성물 및 이의 용도

Legal Events

Date	Code	Title	Description
2009-08-13	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application